Search

Your search keyword '"Merseburger AS"' showing total 3,719 results
Start Over Author "Merseburger AS"
3,719 results on '"Merseburger AS"'

156. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial

Author

Ping Jiang, Katja Krockenberger, Reinhard Vonthein, Jane Tereszczuk, Arne Schreiber, Sebastian Liebau, Stefan Huttenlocher, Detlef Imhoff, Panagiotis Balermpas, Christian Keller, Kathrin Dellas, Rene Baumann, Claus Rödel, Guido Hildebrandt, Klaus-Peter Jünemann, Alex S. Merseburger, Alan Katz, Andreas Ziegler, Oliver Blanck, and Jürgen Dunst

Subjects
Clinical trial, Localized prostate cancer, Extreme hypo-fractionation, Robotic Radiosurgery, Stereotactic body radiation therapy, CyberKnife, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background For prostate cancer treatment, treatment options with minimal side effects are desired. External beam radiation therapy (EBRT) is non-invasive, standard of care and delivered in either conventional fractionation over 8 weeks or with moderate hypo-fractionation over about 5 weeks. Recent advances in radiotherapy technology have made extreme hypo-fractionated stereotactic body radiation therapy (SBRT) of prostate cancer feasible, which has not yet been introduced as a standard treatment method in Germany. Initial results from other countries are promising, but long-term results are not yet available. The aim of this study is to investigate feasibility and effectiveness of SBRT for prostate cancer in Germany. Methods/design This German bi-center single group trial (HYPOSTAT) is designed to evaluate feasibility and effectiveness, as measured by toxicity and PSA-response, respectively, of an extreme hypo-fractionated SBRT regimen with five fractions of 7 Gy in treatment of localized low and intermediate risk prostate cancer. The target volume includes the prostate with or without the base of seminal vesicles depending on risk stratification and uncertainty margins that are kept at 3–5 mm. SBRT treatment is delivered with the robotic CyberKnife system, which was recently introduced in Germany. Acute and late toxicity after one year will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE v. 4.0), Radiation Therapy Oncology Group (RTOG) and International Prostate Symptom Score (IPSS) Scores. The quality of life will be assessed before and after treatment with the EORTC QLQ C30 questionnaire. Hypothesizing that the proportion of patients with grade 2 side effects or higher is less or equal than 2.8%, thus markedly lower than the standard EBRT percentage (17.5%), the recruitment target is 85 patients. Discussion The HYPOSTAT trial aims at demonstrating short term feasibility of extreme hypo-fractioned SBRT for the treatment of prostate cancer and might be used as the pilot study for a multi-center multi-platform or for randomized-controlled trials comparing conventional radiotherapy with SBRT for localized prostate cancer in the future. The study concept of patient enrollment, follow up and evaluation by multiple public university clinics and actual patient treatment in dedicated private radiosurgery practices with high-tech radiation equipment is unique for clinical trials. Study status The study is ongoing and currently recruiting patients. Trial registration Registration number: NCT02635256 ( clinicaltrials.gov ). Registered 8 December 2015.

Published
2017
Full Text
View/download PDF

157. Osteoprotektion als Baustein der Therapie des metastasierten Prostatakarzinoms: Behandlungsrealität in Deutschland und Entscheidungspfade zur Therapieoptimierung

Author

Peter Hammerer, Mario W. Kramer, Jürgen E. Gschwend, Marie C. Hupe, Marten Müller, Thomas Steuber, Julian P. Struck, Tomasz Ozimek, Judith Riccarda Wießmeyer, and Axel S. Merseburger

Subjects
Gynecology, medicine.medical_specialty, business.industry, Urology, 030232 urology & nephrology, medicine.disease, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, business, Real world data
Abstract

Zusammenfassung Hintergrund Die Osteoprotektion bei Prostatakarzinompatienten spielt nicht nur in der ossär metastasierten kastrationsresistenten (mCRPC) Situation eine Rolle. Auch im ossär metastasiertem hormonsensitiven Stadium (mHSPC) und im Allgemeinen begleitend zur Androgendeprivationstherapie (ADT) wird eine Osteoprotektion empfohlen. Diese Studie soll die Anwendungsrealität der verschiedenen Arten der Osteoprotektion beim metastasierten Prostatakarzinom in Deutschland aufzeigen. Material und Methoden Es wurde ein Online-Fragebogen bestehend aus 16 Fragen zur Erfassung der Behandlungsrealität in Deutschland entwickelt und an Mitglieder der Arbeitskreise Onkologie und urologische Onkologie (AKO/AUO) sowie an Kollegen der Klinik für Urologie des Universitätsklinikums Schleswig-Holstein (Campus Lübeck), des Klinikums Braunschweig und der Technischen Universität München verschickt. Mithilfe der aktuellen Studienlage, Fachinformationen und Leitlinien wurden ferner Entscheidungspfade für das ossär metastasierte Prostatakarzinom und für den ADT-induzierten Knochenschwund entwickelt. Ergebnisse Zusammenfassend ergab die Auswertung, dass die Osteoprotektion beim ossär mCRPC zur Routine gehört. Beim ossär mHSPC hingegen wird eine Osteoprotektion seltener indiziert und ist zur Reduktion eines ADT-induzierten Knochenschwundes noch weniger im Einsatz. Denosumab wird häufiger genutzt als Zoledronsäure. Die vorgestellten Entscheidungspfade illustrieren die verschiedenen Dosierungs- und Applikationsschemata in den verschiedenen Stadien des metastasierten Prostatakarzinoms. Schlussfolgerung Die Osteoprotektion beim Prostatakarzinom ist facettenreich und nicht nur auf das ossär mCRPC beschränkt. Osteoprotektive Maßnahmen sind ein wichtiger Baustein im ganzheitlichen Therapiekonzept des metastasierten Prostatakarzinoms.

Published
2022
Full Text
View/download PDF

158. Editorial

Author

Merseburger, Axel S., additional and Kübler, Hubert, additional

Published
2023
Full Text
View/download PDF

159. Impact of Peritoneal Interposition Flap on Patients Undergoing Robot-assisted Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Author

May, Matthias, primary, Gilfrich, Christian, additional, Bründl, Johannes, additional, Ubrig, Burkhard, additional, Wagner, Joseph R., additional, Gloger, Simon, additional, Student, Vladimir, additional, Merseburger, Axel S., additional, Thomas, Christian, additional, Brookman-May, Sabine D., additional, and Wolff, Ingmar, additional

Published
2023
Full Text
View/download PDF

160. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

Author

Kafka, Mona, primary, Horninger, Andreas, additional, di Santo, Gianpaolo, additional, Virgolini, Irene, additional, Neuwirt, Hannes, additional, Unterrainer, Lena M., additional, Kunte, Sophie C., additional, Deiss, Emil, additional, Paffenholz, Pia, additional, Heidenreich, Axel, additional, Rasul, Sazan, additional, Einspieler, Holger, additional, Shariat, Shahrokh F., additional, Rajwa, Pawel, additional, Dozauer, Robert, additional, Tsaur, Igor, additional, Medlock, Ellen, additional, Rölz, Niklas, additional, Rausch, Steffen, additional, la Fougère, Christian, additional, Trautwein, Nils, additional, Roesch, Marie C., additional, Merseburger, Axel S., additional, Zattoni, Fabio, additional, Sepulcri, Matteo, additional, Ladurner, Michael, additional, Bektic, Jasmin, additional, Gandaglia, Giorgio, additional, Horninger, Wolfgang, additional, and Heidegger, Isabel, additional

Published
2023
Full Text
View/download PDF

161. The Role of Urine and Washing Cytology in Primary Transurethral Resection of Bladder Tumours

Author

Struck, Julian P., primary, Ozimek, Tomasz, additional, Schnoor, Maike, additional, Offermann, Anne, additional, Guenther, Marlis, additional, Roesch, Marie C., additional, Wießmeye, Judith R., additional, Katalinic, Alexander, additional, Perner, Sven, additional, Borgmann, Hendrik, additional, Merseburger, Axel S., additional, and Kramer, Mario W., additional

Published
2023
Full Text
View/download PDF

162. Antibody selection influences the detection of AR-V7 in primary prostate cancer

Author

Adam Kaczorowski, Xin Chen, Esther Herpel, Axel S. Merseburger, Glen Kristiansen, Christof Bernemann, Markus Hohenfellner, Marcus V. Cronauer, and Stefan Duensing

Subjects
Prostate cancer, AR-V7, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: The androgen receptor (AR) splice variant V7 (AR-V7) is an emerging marker to aid clinical decision-making in patients with castration-resistant prostate cancer (CRPC). A number of studies have shown that a subset of patients also express AR-V7 in the primary tumor. These findings have recently been challenged by a study showing that AR-V7 becomes only detectable in CRPC but is virtually absent in castration-naïve prostate cancer. Methods: Herein, we directly compare the two relevant antibodies used for the immunodetection of AR-V7 in the conflicting studies (clones AG10008 and RM7) in a predominantly high-risk prostate cancer patient cohort with primary tumor specimens assembled in a tissue microarray (TMA). Results: The overall rate of AR-V7 positive TMA cores was comparable (AG10008, 24.9%; RM7, 21%). However, the percentage agreement of identical staining intensities of positive cores was only 7%. In contrast, the percentage agreement of negative cores was 62.8%. In approximately 30% of the cores, the antibodies produced discordant staining intensities. Only one of the two antibody stainings (AG10008) conveyed prognostic information and was associated with a shorter progression-free patient survival. Conclusions: Our study underscores that nuclear AR-V7 expression can be detected in primary prostate cancer prior to long-term androgen deprivation and castration resistance. There are staining differences between the two antibodies in tumor tissue, for which we currently have no explanation. Clearly, improvements in the detection of functional AR-V7 in prostate cancer are urgently needed.

Published
2020
Full Text
View/download PDF

163. Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter

Author

Seisen, Thomas, Nison, Laurent, Remzi, Mezut, Klatte, Tobias, Mathieu, Romain, Lucca, Ilaria, Bozzini, Grégory, Capitanio, Umberto, Novara, Giacomo, Cussenot, Olivier, Compérat, Eva, Renard-Penna, Raphaële, Peyronnet, Benoit, Merseburger, Axel S., Fritsche, Hans-Martin, Hora, Milan, Shariat, Shahrokh F., Colin, Pierre, and Rouprêt, Morgan

Published
2016
Full Text
View/download PDF

173. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., Omlin, A., Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., and Omlin, A.

Abstract

Item does not contain fulltext, BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage

Published
2023

174. Flappen oder nicht flappen? Ein systematischer Review inkl. Meta-Analyse aller randomisiert-kontrollierten Studien zum Benefit eines Peritoneal-Interposition-Flaps auf das Outcome nach Roboter-assistierter radikaler Prostatektomie mit Lymphadenektomie

Author

Bründl, J, Gilfrich, C, Wolff, I, Thomas, C, Ubrig, B, Wagner, J, Student, V, Merseburger, A, Brookman-May, S, May, M, Bründl, J, Gilfrich, C, Wolff, I, Thomas, C, Ubrig, B, Wagner, J, Student, V, Merseburger, A, Brookman-May, S, and May, M

Published
2023

175. Management of Patients with Advanced Prostate Cancer. Part I:Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Mathew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, Omlin, Aurelius, Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Mathew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Abstract

Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: To present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical man

Published
2023

176. Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's 'big data for better outcomes' program

Author

MS Urologische Oncologie, Cancer, Gomez Rivas, Juan, Nicoletti, Rossella, Ibáñez, Laura, Steinbeisser, Carl, de Meulder, Bertrand, Golozar, Asieh, Axelsson, Susan Evans, Snijder, Robert, Bjartell, Anders, Cornford, Philip, Van Hemelrijck, Mieke, Beyer, Katharina, Willemse, Peter-Paul, Murtola, Teemu, Roobol, Monique J, Moreno-Sierra, Jesús, Campi, Riccardo, Gacci, Mauro, Mottet, Nicolas, Merseburger, Axel, Ndow, James, MS Urologische Oncologie, Cancer, Gomez Rivas, Juan, Nicoletti, Rossella, Ibáñez, Laura, Steinbeisser, Carl, de Meulder, Bertrand, Golozar, Asieh, Axelsson, Susan Evans, Snijder, Robert, Bjartell, Anders, Cornford, Philip, Van Hemelrijck, Mieke, Beyer, Katharina, Willemse, Peter-Paul, Murtola, Teemu, Roobol, Monique J, Moreno-Sierra, Jesús, Campi, Riccardo, Gacci, Mauro, Mottet, Nicolas, Merseburger, Axel, and Ndow, James

Published
2023

177. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration:Final Results from the Phase 2 TRITON2 Study

Author

Abida, Wassim, Campbell, David, Patnaik, Akash, Bryce, Alan H., Shapiro, Jeremy, Bambury, Richard M., Zhang, Jingsong, Burke, John M., Castellano, Daniel, Font, Albert, Ganju, Vinod, Hardy-Bessard, Anne Claire, McDermott, Ray, Sautois, Brieuc, Spaeth, Dominique, Voog, Eric, Piulats, Josep M., Pintus, Elias, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Loehr, Andrea, Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Go, Jowell, Watkins, Simon P., Chowdhury, Simon, Abida, Wassim, Campbell, David, Patnaik, Akash, Bryce, Alan H., Shapiro, Jeremy, Bambury, Richard M., Zhang, Jingsong, Burke, John M., Castellano, Daniel, Font, Albert, Ganju, Vinod, Hardy-Bessard, Anne Claire, McDermott, Ray, Sautois, Brieuc, Spaeth, Dominique, Voog, Eric, Piulats, Josep M., Pintus, Elias, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Loehr, Andrea, Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Go, Jowell, Watkins, Simon P., and Chowdhury, Simon

Abstract

Background: Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA1 or BRCA2 (BRCA) or other DNA damage repair (DDR) gene alteration. Objective: To present the final data from TRITON2. Design, setting, and participants: TRITON2 enrolled patients with mCRPC who had progressed on one or two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy. Outcome measurements and statistical analysis: The primary endpoint was objective response rate (ORR; as per the modified Response Evaluation Criteria in Solid Tumor Version 1.1/Prostate Cancer Clinical Trials Working Group 3 criteria in patients with measurable disease by independent radiology review [IRR]); prostate-specific antigen (PSA) response rate (≥50% decrease from baseline [PSA50]) was a key secondary endpoint. Results and limitations: As of July 27, 2021 (study closure), TRITON2 had enrolled 277 patients, grouped by mutated gene: BRCA (n = 172), ATM (n = 59), CDK12 (n = 15), CHEK2 (n = 7), PALB2 (n = 11), or other DDR gene (Other; n = 13). ORR by IRR was 46% (37/81) in the BRCA subgroup (95% confidence interval [CI], 35–57%), 100% (4/4) in the PALB2 subgroup (95% CI, 40–100%), and 25% (3/12) in the Other subgroup (95% CI, 5.5–57%). No patients within the ATM, CDK12, or CHEK2 subgroups had an objective response by IRR. PSA50 response rates (95% CI) in the BRCA, PALB2, ATM, CDK12, CHEK2, and Other subgroups were 53% (46–61%), 55% (23–83%), 3.4% (0.4–12), 6.7% (0.2–32%), 14% (0.4–58%), and 23% (5.0–54%), respectively. Conclusions: The final TRITON2 results confirm the clinical benefit and manageable safety profile of rucaparib in patients with mCRPC, including those with an alteration in BRCA or select non-BRCA DDR gene. Patient summary: Almost half of TRITON2 patients with BRCA-mutated metastatic castration-resistant prostate cancer had a complete or

Published
2023

179. CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Agarwal, Neeraj, Azad, Arun, Carles, Joan, Matsubara, Nobuaki, Oudard, Stephane, Saad, Fred, Merseburger, Axel S., Soares, Andrey, McGregor, Bradley Alexander, Zurawski, Bogdan, North, Scott A., Tsiatas, Marinos, Bondarenko, Igor, Alfie, Margarita Sonia, Evilevitch, Lena, Sharma, Keerti, Nandoskar, Prachi, Ferraldeschi, Roberta, Wang, Fong, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

180. Centralizing Penile Cancer Care in Germany and Austria: Just a Dream or a Fast-Approaching Reality? Results of a Survey Study among Urological Department Chairs and Modeling of Real Treatment Numbers of Penile Cancer Patients.

Author

Yakac, Abdulbaki, Lebentrau, Steffen, Lusuardi, Lukas, Sarcan, Semih, Burger, Maximilian, Merseburger, Axel S., Wiegland, Jens, Gilfrich, Christian, Wolff, Ingmar, Ahyai, Sascha, May, Matthias, and Thomas, Christian

Subjects
PENILE cancer, CANCER treatment, CANCER patients, UNIVERSITY hospitals, ACADEMIC departments
Abstract

Introduction: In countries characterized by a centralization of therapy management, patients with penile cancer (PeCa) have shown improvements in guideline adherence and ultimately, improved carcinoma-specific survival. Germany and Austria (G + A) have no state-regulated centralization of PeCa management, and the perspectives of urological university department chairs (UUDCs) in these countries, who act as drivers of professional and political developments, on this topic are currently unknown. Methods: Surveys containing 36 response options, including specific questions regarding perspectives on PeCa centralization, were sent to the 48 UUDC in G + A in January 2023. In addition to analyzing the responses, closely following the CROSS checklist, a modeling of the real healthcare situation of in-house PeCa patients in G + A was conducted. Results: The response rate was 75% (36/48). 94% and 89% of the UUDCs considered PeCa centralization meaningful and feasible in the medium term, respectively. Among the UUDCs, 72% estimated centralization within university hospitals as appropriate, while 28% favored a geographically oriented approach. Additionally, 97% of the UUDCs emphasized the importance of bridging the gap until implementation of centralization by establishing PeCa second-opinion portals. No country-specific differences were observed. The median number of in-house PeCa cases at the university hospitals in G + A was 13 (interquartile range: 9–26). A significant positive correlation was observed between the annual number of in-house PeCa cases at a given university hospital and the perspective of the UUDCs that centralization as meaningful by its UUDC (0.024). Under assumptions permissible for modeling, the average number of in-house PeCa cases in academic hospitals in G + A was approximately 30 times higher than in nonacademic hospitals. Conclusion: This study provides the first data on the perspectives of UUDCs in G + A concerning centralization of PeCa therapy management. Even without state-regulated centralization in G + A, there is currently a clear focusing of PeCa treatments in university hospitals. Further necessary steps toward a structured PeCa centralization are discussed in this manuscript. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

181. Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program.

Author

Gomez Rivas, Juan, Nicoletti, Rossella, Ibáñez, Laura, Steinbeisser, Carl, de Meulder, Bertrand, Golozar, Asieh, Evans Axelsson, Susan, Snijder, Robert, Bjartell, Anders, Cornford, Philip, Van Hemelrijck, Mieke, Beyer, Katharina, Willemse, Peter-Paul, Murtola, Teemu, Roobol, Monique J., Moreno-Sierra, Jesús, Campi, Riccardo, Gacci, Mauro, Mottet, Nicolas, and Merseburger, Axel

Published
2023
Full Text
View/download PDF

187. Data from β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer

Author

Kallifatidis, Georgios, primary, Smith, Diandra K., primary, Morera, Daley S., primary, Gao, Jie, primary, Hennig, Martin J., primary, Hoy, James J., primary, Pearce, Richard F., primary, Dabke, Isha R., primary, Li, Jiemin, primary, Merseburger, Axel S., primary, Kuczyk, Markus A., primary, Lokeshwar, Vinata B., primary, and Lokeshwar, Bal L., primary

Published
2023
Full Text
View/download PDF

188. Supplementary Tables 1-4 and Supplementary Figures S1 to S7; and Supplementary Materials and Methods from β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer

Author

Kallifatidis, Georgios, primary, Smith, Diandra K., primary, Morera, Daley S., primary, Gao, Jie, primary, Hennig, Martin J., primary, Hoy, James J., primary, Pearce, Richard F., primary, Dabke, Isha R., primary, Li, Jiemin, primary, Merseburger, Axel S., primary, Kuczyk, Markus A., primary, Lokeshwar, Vinata B., primary, and Lokeshwar, Bal L., primary

Published
2023
Full Text
View/download PDF

189. Suppl Fig S1 from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Author

Abida, Wassim, primary, Campbell, David, primary, Patnaik, Akash, primary, Shapiro, Jeremy D., primary, Sautois, Brieuc, primary, Vogelzang, Nicholas J., primary, Voog, Eric G., primary, Bryce, Alan H., primary, McDermott, Ray, primary, Ricci, Francesco, primary, Rowe, Julie, primary, Zhang, Jingsong, primary, Piulats, Josep Maria, primary, Fizazi, Karim, primary, Merseburger, Axel S., primary, Higano, Celestia S., primary, Krieger, Laurence E., primary, Ryan, Charles J., primary, Feng, Felix Y., primary, Simmons, Andrew D., primary, Loehr, Andrea, primary, Despain, Darrin, primary, Dowson, Melanie, primary, Green, Foad, primary, Watkins, Simon P., primary, Golsorkhi, Tony, primary, and Chowdhury, Simon, primary

Published
2023
Full Text
View/download PDF

190. Supplementary Data from HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer

Author

Hasanali, Sarrah L., primary, Morera, Daley S., primary, Racine, Ronny R., primary, Hennig, Martin, primary, Ghosh, Santu, primary, Lopez, Luis E., primary, Hupe, Marie C., primary, Escudero, Diogo O., primary, Wang, Jiaojiao, primary, Zhu, Huabin, primary, Sarcan, Semih, primary, Azih, Ijeoma, primary, Zhou, Michael, primary, Jordan, Andre R., primary, Terris, Martha K., primary, Kuczyk, Markus A., primary, Merseburger, Axel S., primary, and Lokeshwar, Vinata B., primary

Published
2023
Full Text
View/download PDF

191. Supplementary Data from Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer

Author

Brägelmann, Johannes, primary, Klümper, Niklas, primary, Offermann, Anne, primary, von Mässenhausen, Anne, primary, Böhm, Diana, primary, Deng, Mario, primary, Queisser, Angela, primary, Sanders, Christine, primary, Syring, Isabella, primary, Merseburger, Axel S., primary, Vogel, Wenzel, primary, Sievers, Elisabeth, primary, Vlasic, Ignacija, primary, Carlsson, Jessica, primary, Andrén, Ove, primary, Brossart, Peter, primary, Duensing, Stefan, primary, Svensson, Maria A., primary, Adler, David, primary, Kirfel, Jutta, primary, and Perner, Sven, primary

Published
2023
Full Text
View/download PDF

192. Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Author

Frantzi, Maria, primary, van Kessel, Kim E., primary, Zwarthoff, Ellen C., primary, Marquez, Mirari, primary, Rava, Marta, primary, Malats, Núria, primary, Merseburger, Axel S., primary, Katafigiotis, Ioannis, primary, Stravodimos, Konstantinos, primary, Mullen, William, primary, Zoidakis, Jerome, primary, Makridakis, Manousos, primary, Pejchinovski, Martin, primary, Critselis, Elena, primary, Lichtinghagen, Ralph, primary, Brand, Korbinian, primary, Dakna, Mohammed, primary, Roubelakis, Maria G., primary, Theodorescu, Dan, primary, Vlahou, Antonia, primary, Mischak, Harald, primary, and Anagnou, Nicholas P., primary

Published
2023
Full Text
View/download PDF

193. Supplementary Figures from Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Author

Loehr, Andrea, primary, Patnaik, Akash, primary, Campbell, David, primary, Shapiro, Jeremy, primary, Bryce, Alan H., primary, McDermott, Ray, primary, Sautois, Brieuc, primary, Vogelzang, Nicholas J., primary, Bambury, Richard M., primary, Voog, Eric, primary, Zhang, Jingsong, primary, Piulats, Josep M., primary, Hussain, Arif, primary, Ryan, Charles J., primary, Merseburger, Axel S., primary, Daugaard, Gedske, primary, Heidenreich, Axel, primary, Fizazi, Karim, primary, Higano, Celestia S., primary, Krieger, Laurence E., primary, Sternberg, Cora N., primary, Watkins, Simon P., primary, Despain, Darrin, primary, Simmons, Andrew D., primary, Dowson, Melanie, primary, Golsorkhi, Tony, primary, Chowdhury, Simon, primary, and Abida, Wassim, primary

Published
2023
Full Text
View/download PDF

195. Radiomics vs radiologist in prostate cancer. Results from a systematic review

Author

Chiacchio, Giuseppe, primary, Castellani, Daniele, additional, Nedbal, Carlotta, additional, De Stefano, Virgilio, additional, Brocca, Carlo, additional, Tramanzoli, Pietro, additional, Galosi, Andrea Benedetto, additional, Donalisio da Silva, Rodrigo, additional, Teoh, Jeremy Yuen-Chun, additional, Tiong, Ho Yee, additional, Naik, Nithesh, additional, Somani, Bhaskar K., additional, Merseburger, Axel S., additional, and Gauhar, Vineet, additional

Published
2023
Full Text
View/download PDF

196. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, primary, Bossi, Alberto, additional, Davis, Ian D., additional, de Bono, Johann, additional, Fizazi, Karim, additional, James, Nicholas D., additional, Mottet, Nicolas, additional, Shore, Neal, additional, Small, Eric, additional, Smith, Matthew, additional, Sweeney, Christopher, additional, Tombal, Bertrand, additional, Antonarakis, Emmanuel S., additional, Aparicio, Ana M., additional, Armstrong, Andrew J., additional, Attard, Gerhardt, additional, Beer, Tomasz M., additional, Beltran, Himisha, additional, Bjartell, Anders, additional, Blanchard, Pierre, additional, Briganti, Alberto, additional, Bristow, Rob G., additional, Bulbul, Muhammad, additional, Caffo, Orazio, additional, Castellano, Daniel, additional, Castro, Elena, additional, Cheng, Heather H., additional, Chi, Kim N., additional, Chowdhury, Simon, additional, Clarke, Caroline S., additional, Clarke, Noel, additional, Daugaard, Gedske, additional, De Santis, Maria, additional, Duran, Ignacio, additional, Eeles, Ros, additional, Efstathiou, Eleni, additional, Efstathiou, Jason, additional, Ngozi Ekeke, Onyeanunam, additional, Evans, Christopher P., additional, Fanti, Stefano, additional, Feng, Felix Y., additional, Fonteyne, Valerie, additional, Fossati, Nicola, additional, Frydenberg, Mark, additional, George, Daniel, additional, Gleave, Martin, additional, Gravis, Gwenaelle, additional, Halabi, Susan, additional, Heinrich, Daniel, additional, Herrmann, Ken, additional, Higano, Celestia, additional, Hofman, Michael S., additional, Horvath, Lisa G., additional, Hussain, Maha, additional, Jereczek-Fossa, Barbara Alicja, additional, Jones, Robert, additional, Kanesvaran, Ravindran, additional, Kellokumpu-Lehtinen, Pirkko-Liisa, additional, Khauli, Raja B., additional, Klotz, Laurence, additional, Kramer, Gero, additional, Leibowitz, Raya, additional, Logothetis, Christopher J., additional, Mahal, Brandon A., additional, Maluf, Fernando, additional, Mateo, Joaquin, additional, Matheson, David, additional, Mehra, Niven, additional, Merseburger, Axel, additional, Morgans, Alicia K., additional, Morris, Michael J., additional, Mrabti, Hind, additional, Mukherji, Deborah, additional, Murphy, Declan G., additional, Murthy, Vedang, additional, Nguyen, Paul L., additional, Oh, William K., additional, Ost, Piet, additional, O'Sullivan, Joe M., additional, Padhani, Anwar R., additional, Pezaro, Carmel, additional, Poon, Darren M.C., additional, Pritchard, Colin C., additional, Rabah, Danny M., additional, Rathkopf, Dana, additional, Reiter, Robert E., additional, Rubin, Mark. A., additional, Ryan, Charles J., additional, Saad, Fred, additional, Pablo Sade, Juan, additional, Sartor, Oliver A., additional, Scher, Howard I., additional, Sharifi, Nima, additional, Skoneczna, Iwona, additional, Soule, Howard, additional, Spratt, Daniel E., additional, Srinivas, Sandy, additional, Sternberg, Cora N., additional, Steuber, Thomas, additional, Suzuki, Hiroyoshi, additional, Sydes, Matthew R., additional, Taplin, Mary-Ellen, additional, Tilki, Derya, additional, Türkeri, Levent, additional, Turco, Fabio, additional, Uemura, Hiroji, additional, Uemura, Hirotsugu, additional, Ürün, Yüksel, additional, Vale, Claire L., additional, van Oort, Inge, additional, Vapiwala, Neha, additional, Walz, Jochen, additional, Yamoah, Kosj, additional, Ye, Dingwei, additional, Yu, Evan Y., additional, Zapatero, Almudena, additional, Zilli, Thomas, additional, and Omlin, Aurelius, additional

Published
2023
Full Text
View/download PDF

198. Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer

Author

Anne Offermann, Vincent Joerg, Finn Becker, Marie C. Roesch, Duan Kang, Anna-Lena Lemster, Lars Tharun, Jochen Behrends, Axel S. Merseburger, Zoran Culig, Verena Sailer, Johannes Brägelmann, Jutta Kirfel, and Sven Perner

Subjects
Male, Carcinogenesis, Androgens, Humans, Prostatic Neoplasms, Androgen Antagonists, Cyclin-Dependent Kinase 8, Cyclin-Dependent Kinases, Pathology and Forensic Medicine
Abstract

Progression of prostate cancer (PCa) is characterized by metastasis and castration resistance after response to androgen deprivation. Therapeutic options are limited, causing high morbidity and lethality. Recent work reported pro-oncogenic implications of the Mediator subunits cyclin-dependent kinase (CDK) 8 and 19 for the progression of PCa. The current study explored the underlying molecular mechanisms of CDK8/CDK19 and tested effects of novel CDK8/CDK19 inhibitors. PC3, DU145, LNCaP, and androgen-independent LNCaP Abl were used for in vitro experiments. Two inhibitors and CDK19 overexpression were used to modify CDK8/CDK19 activity. MTT assay, propidium iodide staining, wound healing assay, Boyden chamber assay, and adhesion assay were used to investigate cell viability, cell cycle, migration, and adhesion, respectively. Peptide-kinase screen using the PamGene platform was conducted to identify phosphorylated targets. Combining CDK8/CDK19 inhibitors with anti-androgens led to synergistic antiproliferative effects and sensitized androgen-independent cells to bicalutamide. CDK8/CDK19 inhibition resulted in reduced migration and increased collagen I-dependent adhesion. Phosphorylation of multiple peptides linked to cancer progression was identified to be dependent on CDK8/CDK19. In summary, this study substantially supports recent findings on CDK8/CDK19 in PCa progression. These findings contribute to a better understanding of underlying pro-oncogenic effects, which is needed to develop CDK8/CDK19 as a therapeutic target in PCa.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results